Novelty enhancement is defined as a feeling of increased fascination, awe, and appreciation attributed to specific parts or the entirety of one's external environment. This can result in an often overwhelming impression that everyday concepts such as nature, existence, common events, and even household objects are now considerably more profound, interesting, and significant.
The experience of this effect commonly forces those who undergo it to acknowledge, consider, and appreciate the things around them in a level of detail and intensity which remains largely unparalleled throughout every day sobriety. It is often generally described using phrases such as "a sense of wonder" or "seeing the world as new".
Novelty enhancement is often accompanied by other coinciding effects such as personal bias suppression, emotion enhancement and spirituality enhancement in a manner which further intensifies the experience. It is most commonly induced under the influence of moderate dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline. However, it can also occur to a lesser extent under the influence of cannabinoids, dissociatives, and entactogens.
Compounds within our psychoactive substance index which may cause this effect include:
Anecdotal reports which describe this effect within our experience index include:
- Experience: 22mg 2C-B (oral) / 100ug 1P-LSD (sublingual) - My first time tripping alone (2 days in a row)
- Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us
- Experience: 5-EAPB (60mg) + 2-FMA (20mg) + 4-AcO-DMT (10mg) - Emotional catharsis
- Experience:12 mg AMT - Nicely Surprised
- Experience:150mg MDMA + 20mg 2C-B - I designed it this way myself
- Experience:2 tabs DOB - My DOB Nightmare
- Experience:2.5g - Swim's first mushroom trip
- Experience:225ug - Sheer Awe and Joy
- Experience:250mg MDA / 250mg MDMA - unnecessarily large dosage
- Experience:25mg - A labyrinth of organs and a storybook walk
- Experience:25mg 3-MeO-PCP - Enhanced film experience
- Experience:25mg Deschloroketamine - My first time orally dosing DCK
- Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective
- Experience:3.5g psilocybe cubensis - Relinquishing of Material Chains/Fear and Desolation
- Experience:300ug LSD - Profound religious experience
- Experience:300µg LSD - Togetherness and the Silent Dusk
- Experience:337mg DMT fumarate - A Day With DMT
- Experience:4.5g - The Grand Introduction to Beauty and Fear
- Experience:40mg - Brothermind and the Forest's Hand
- Experience:4x 200ug tabs - You do not need to understand
- Experience:6g mimosa / 2.5 g syrian rue - Best cake I've had for a while
- Experience:750mg - Experiencing Void; Dissociation Of Reality And Self
- Experience:800ug LSD - 3D Vision
- Experience:DMT (~50mg) + Cannabis - Geometric Angels
- Experience:LSD (150µg) + Cannabis - 150µg lsd and a shitload of weed
- Experience:Mushrooms (~0.5 g) - Autonomous Voice
- Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams)
- Experience:Nutmeg (8 teaspoons) - My Mom Introduces Me To Genesis and Other Things
- Responsible use
- Subjective effects index
- Psychedelics - Subjective effects
- Dissociatives - Subjective effects
- Deliriants - Subjective effects
- Hunt, Harry T. (1976). "A Test of the Psychedelic Model of Altered States of Consciousness". Archives of General Psychiatry. 33 (7): 867. doi:10.1001/archpsyc.1976.01770070097012. ISSN 0003-990X.
- Bonner, Edward T.; Friedman, Harris L. (2011). "A conceptual clarification of the experience of awe: An interpretative phenomenological analysis". The Humanistic Psychologist. 39 (3): 222–235. doi:10.1080/08873267.2011.593372. ISSN 1547-3333.
- Griffiths, Roland R; Johnson, Matthew W; Richards, William A; Richards, Brian D; Jesse, Robert; MacLean, Katherine A; Barrett, Frederick S; Cosimano, Mary P; Klinedinst, Maggie A (2017). "Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors". Journal of Psychopharmacology. 32 (1): 49–69. doi:10.1177/0269881117731279. ISSN 0269-8811.
- Das, Saibal; Barnwal, Preeti; Ramasamy, Anand; Sen, Sumalya; Mondal, Somnath (2016). "Lysergic acid diethylamide: a drug of 'use'?". Therapeutic Advances in Psychopharmacology. 6 (3): 214–228. doi:10.1177/2045125316640440. ISSN 2045-1253.
- Bowers, Malcolm B. (1966). ""Psychedelic" Experiences in Acute Psychoses". Archives of General Psychiatry. 15 (3): 240. doi:10.1001/archpsyc.1966.01730150016003. ISSN 0003-990X.
- Belser, Alexander B.; Agin-Liebes, Gabrielle; Swift, T. Cody; Terrana, Sara; Devenot, Neşe; Friedman, Harris L.; Guss, Jeffrey; Bossis, Anthony; Ross, Stephen (2017). "Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis". Journal of Humanistic Psychology. 57 (4): 354–388. doi:10.1177/0022167817706884. ISSN 0022-1678.